Figure 2.
Personalized models to guide precision medicine in advanced cancer. Illustration of our precision medicine program depicting the workflow, beginning with sequencing using the EXaCT-1 whole exome sequencing test (top row), continuing with the establishment of PDTOs, which are compared to the primary tumor sample through histology and sequencing before they are subjected to drug screening (middle row), and utilized to generate PDXs where potential drugs are validated in mice (bottom row). The sequencing data is available in our internal cbio-portal and reported back to the referring physician. Tumor organoid cultures are prepared from fresh patient tumor samples as personalized in vitro models. After the initial characterization, targeted or high throughput single and combination drug screens can be performed in an iterative process in order to nominate therapeutic strategies that are further evaluated in personalized in vivo models.